– First patient dosed in Phase 2 study of ANX005 C1q targeted mAb – “Huntington’s Disease is a devastating, progressive movement disorder with no cure and no approved therapeutic options available to ...

Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated macrophage/microglial activation — two key drivers of neuroinflammationMB0109 demonstrated ...

Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...

Immunoglobulin A (IgA) nephropathy results from the accumulation of IgA-containing immune complexes (IgA-ICs) and aberrant ...

Complement activation in patients with AAV who are in remission may be reflective of ongoing renal scarring. Persistent complement activation during disease remission in antineutrophil cytoplasmic ...

In a recent study posted to the bioRxiv* pre-print server, researchers investigated the complement component 1q (C1q) binding and subsequent complement activation by neutralizing antibodies (nAbs) ...

A study shows elevated CFHR1 promotes immune complex buildup in kidneys, offering insights into disease mechanisms, enabling ...

Target Levels of Active Drug Achieved in Healthy Volunteers with Oral Twice-Daily Dosing; Supportive Impact on Pharmacodynamic Biomarker of Complement Activity ANX1502 Generally Well Tolerated Across ...